peptides stroke FAQ

Stronger than for primary prevention. Post-stroke cognitive impairment affects 20–50% of survivors, and traditional therapies (cholinesterase inhibitors, cognitive rehabilitation) show limited efficacy. Cerebrolysin improved cognitive outcomes (MMSE scores, verbal fluency) in several post-stroke dementia trials, though effect sizes were modest. P21 enhanced spatial learning in post-stroke rodent models. Human translation is speculative but biologically plausible. Dihexa showed cognitive improvements in aged rats and TBI models, suggesting potential for stroke-related deficits. Protocols might explore 3–6 month courses starting weeks after the acute event, targeting neuroplasticity during the critical recovery window.

Start with Cerebrolysin under medical supervision. Observational data shows 22% recurrence reduction in stroke survivors using it as adjunctive therapy alongside standard anticoagulation and statin protocols. The compound works by mimicking endogenous neurotrophic factors that promote synaptic repair and reduce excitotoxic neuronal death during transient ischemia. Typical protocols involve 30–50ml IV infusions over 10–20 days, repeated every 3–6 months. This isn't a replacement for aspirin or statins. It's an add-on targeting mechanisms conventional medications don't address.

The benefit shifts from acute infarct limitation to neuroplasticity support during recovery. Cerebrolysin trials showed diminishing effect sizes when administration started beyond 48 hours post-stroke, but some functional improvement persisted even at 72 hours. P21's mechanism. Promoting dendritic spine formation and synaptic remodeling. Suggests value during the weeks-to-months rehabilitation phase, not just the acute hours. Dihexa's neurogenesis-promoting activity similarly supports long-term recovery. The compounds don't become useless outside the acute window. They just serve a different therapeutic goal: enhancing compensatory plasticity rather than preventing cell death.

No. These compounds don't prevent clot formation, reduce atherosclerotic plaque burden, or lower blood pressure. The mechanisms that actually stop strokes from occurring. Primary prevention requires antiplatelet therapy (aspirin, clopidogrel), anticoagulation for atrial fibrillation patients, statin therapy for cholesterol management, and blood pressure control. Peptides like Cerebrolysin, P21, and Dihexa function as neuroprotective agents during and after ischemic injury. They reduce damage severity once blood flow is compromised, but they don't address the vascular pathology that causes strokes.

If your CRP, IL-6, or TNF-α levels are persistently elevated (above the 75th percentile for your age group), Thymalin targets the chronic inflammation that damages endothelial cells and increases plaque instability. Research shows 30–35% reductions in circulating inflammatory cytokines over 12 weeks at 10–20mg subcutaneous doses 2–3 times weekly. The effect is systemic, not CNS-direct. It reduces the inflammatory load that contributes to blood-brain barrier breakdown during ischemic events. Pair it with standard care, not as monotherapy.

Dihexa is the most promising compound for dual cognitive enhancement and neuroprotection, though human stroke data doesn't exist yet. Preclinical models show 30–40% increases in hippocampal synaptic density within weeks, and the compound protects neurons from excitotoxic death in ischemia models. Oral bioavailability is ~50%, making it practical for daily use at 5mg doses. The trade-off: you're using a compound with Phase I safety data but no Phase II efficacy trials in humans. That's an acceptable risk profile for research use but not yet a clinical recommendation.